Federal: Other MH Policy

The federal promotion of deprescribing as standard mental health vocabulary signals a fundamental shift in how psychiatric medication is positioned within the broader treatment landscape—and this directly affects your referral relationships, patient conversations, and billing opportunities. If HHS-backed deprescribing guidance becomes embedded in Medicare policy and SAMHSA technical assistance materials, you should expect two parallel developments: first, patients will arrive at your office already primed to question psychiatric medications, potentially creating friction with prescribing providers who haven't adopted this framework; second, Medicare may expand reimbursement for medication tapering counseling and 'holistic care coordination' sessions, creating new billable activities for therapists who can document clinical rationale for these services. However, this expansion cuts both ways. While you may bill for additional counseling around medication reduction, insurance carriers could simultaneously cite deprescribing guidance to deny coverage for psychiatric medication management itself—particularly for patients on long-term antidepressants or anxiolytics. Your income risk depends on your current payer mix: Medicaid-heavy practices will feel this sooner than commercial-insured practices, since state Medicaid programs often adopt federal HHS guidance rapidly. The most immediate compliance burden falls on you if you're billing for medication management alongside deprescribing counseling; you'll need to document whether you're supporting continuation, adjustment, or planned reduction of psychiatric meds, since inconsistent documentation could trigger audits from payers interpreting this guidance as a mandate rather than an option.